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(p=0.0079). Conclusion : Our data in unselected population of MI patients indicate for
the first time that IFG is associated with an increased mortality rate, which is mainly due
to an higher risk for developing cardiogenic shock during in-hospital stay .
1021-97 Impact of Diabetes Mellitus on Thrombolysis in 
Myocardial Infarction Risk Score, Procedural Utilization, 
and Clinical Outcomes in Minorities and Women as 
Compared to White Men With Non-ST-Segment 
Elevation Acute Coronary Syndrome
Muhammad Rizwan Khalid, Fawad Kazi, Justin Brezina Lundbye, Anita M. Kelsey, 
Raymond G. McKay, Roger Mennett, William E. Boden, University of Connecticut Health 
Center, Farmington, CT, Hartford Hospital, Hartford, CT
Introduction: It is well-recognized that diabetics with coronary heart disease , compared
to non-diabetics, are at significantly increased risk for subsequent cardiac events, but it is
unclear whether diabetics who present with non-ST-segment elevation (NSTE) acute cor-
onary syndrome (ACS) have differential rates of procedural utilization, TIMI Risk Score
(TRS) and clinical outcomes among various gender and racial subsets. Accordingly, the
purpose of the present study was to assess TRS, procedural utilization rates of cardiac
catheterization, and clinical outcomes using composite major adverse clinical events
(MACE) for diabetic and non-diabetic subsets of whites, non-whites, men and women
patients hospitalized with NSTE ACS.
Methods: A total of 2,432 NSTE ACS patients could be classified according to the pub-
lished TIMI risk score. Clinical outcomes using a MACE composite (death, MI, stroke,
need for urgent revascularization) were assessed for diabetic and non-diabetic subsets of
varying race and gender.
Results: Diabetics presented with a significantly higher TRS when compared to non-dia-
betics (4.02 vs. 3.56; P<0.001). Non-diabetics underwent more cardiac interventions
compared to diabetics (P<0.05). However, as expected, diabetics were more likely to
experience MACE (P<0.05) when compared to non-diabetics during follow-up ranging
from 30-180 days. Diabetics who did not undergo cardiac catheterization had a signifi-
cantly higher incidence of MACE (P<0.01) compared to non-diabetics, but there was no
significant gender and racial differences in MACE rates in the diabetic subgroup.
Conclusion: Although diabetic patients who present with NSTE ACS have significantly
higher TIMI Risk Scores at hospitalization and higher MACE during follow-up compared
to non-diabetics, our single-site experience revealed that there were no significant gen-
der or racial differences noted among white and non-white men or women. Paradoxically,
we noted that diabetic patients with NSTE ACS were less likely to undergo cardiac cath-
eterization than non-diabetics, but importantly, diabetics who did not undergo cardiac
catheterization appeared to fare worse than those who underwent intervention.
1021-98 Is Metabolic Dysfunction Equivalent to Diabetes as a 
Prognostic Marker in Acute Coronary Syndrome?
Pedro Araujo Goncalves, Jorge Ferreira, Luis Raposo, Carlos Aguiar, Ricardo Seabra-
Gomes, Hospital de Santa Cruz, Carnaxide, Portugal
Background: Diabetes mellitus (D) is a known prognostic marker in patients with acute
coronary syndromes (ACS). Recently, a constellation of lipid and non lipid risk factor
linked to insulin resistance was described and termed metabolic syndrome. We have pre-
viously demonstrated the independent prognostic value of a metabolic score (MS), but Its
interaction with D, as a prognostic marker in ACS, is not yet established.
Methods: We studied 302 patients with non-ST segment elevation ACS. A MS was calcu-
lated using the following variables collected on admission: obesity (BMI>30Kg/m2);
Blood pressure>130/85mmHg; Triglycerides>150mg/dl; HDL<40mg/dl (or <50mg/dl in
women); blood glucose >or= 110mg/dl. With the cut-off identified for the MS (>3 vari-
ables), we divided our population into 4 groups: D & MS; D & No MS; No D & MS; No D &
No MS. The endpoint used was the combined incidence of death and myocardial infarc-
tion at 1 year follow-up.
Results: Patients D & MS (n=30 ) had the highest study endpoint (23.3%), and the lowest
incidence was 10.3% for No D & No MS (n=204). The incidence of the study endpoint
was similar in the other 2 groups: 22.7% for ND & MS (n=22) and 21.7% for D & NMS
(n=46).
Conclusions: The presence of metabolic dysfunction in non-diabetic patients, was asso-
ciated to a poorer prognosis, as observed in diabetic patients. In patients with diabetes,
detection of metabolic dysfunction, as evaluated with the best cut-off for this score,
seems to add no aditional prognostic information.
1021-99 Metabolic Syndrome: A Major Risk Factor for Acute 
Myocardial Infarction in Patients < 45 Years of Age
Carlo Luciano, Jacqueline Hulford, Arif Abdullah, Stuart Zarich, Bridgeport Hospital, 
Bridgeport, CT, Yale University School of Medicine, New Haven, CT
Introduction: Premature coronary artery disease (CAD) is not fully explained by tradi-
tional global risk scores. Less than 25% of young adults with acute myocardial infarction
(MI) meet NCEP III criteria for pharmacotherapy. As insulin resistance is associated with
an increased risk of myocardial infarction (MI), we hypothesized that the metabolic syn-
drome (MS) is a major unrecognized risk factor for MI in young patients. Methods: We
studied 196 consecutive patients (<45yrs old) with acute MI treated at Bridgeport Hospi-
tal from January 1999 through July 2003. MI was defined as both ST elevation or non-ST
elevation MI by the usual criteria. MS was defined according to NCEP III guidelines (> 3
of five criteria with a body mass index >30kg/m2 substituted for waist circumference).
Results: For the entire cohort the mean age was 41.3 years, with a BMI of 29.8, LDL of
124 mg/dl, HDL of 36 mg/dl and triglycerides of 216 mg/dl. Of the 165 patients in whom
all 5 criteria for MS were evaluable at or before the time of MI, 63(38%) met the diagnos-
tic criteria for the MS in the absence of diabetes (DM). An additional 38 patients (23%)
had newly diagnosed or previously recognized DM. A history of cigarette use was seen
more frequently in non-MS as compared to MS patients (81% vs 66%; p=0.01), while a
family history of accelerated CVD, total cholesterol, and LDL levels were similar in both
groups. Only 19% met MS criteria based on an elevated fasting glucose. The mean 10
year Framingham risk score in non-diabetics was 9.3% (only 17.1% had scores greater
than 20%). Conclusion: MS and/or overt DM are present in nearly 2/3 of young patients
with acute MI. The presence of the MS should alert physicians to the need for aggressive
risk factor and lifestyle modifications, even in the absence of high global risk scores.
1021-100 Metabolic Syndrome: An Underecognized Risk Factor 
for Myocardial Infarction in the Young
Patrick J. Curran, Eugene H. Chung, Manish S. Chauhan, Christopher T. Pyne, Thomas 
C. Piemonte, David E. Gossman, James Waters, Seth Bilazarian, Khether Raby, Nabila 
Riskala, Richard W. Nesto, Lahey Clinic, Burlington, MA
Background: Risk factors for coronary heart disease (CHD) typically associated with
acute myocardial infarction (MI) in the young (< 45yrs of age) are smoking and familial
hypercholesterolemia. We hypothesized that metabolic syndrome (MS) is an underrecog-
nized major risk factor in these patients.
Methods: We studied 132 consecutive young patients with acute MI (ST and non ST ele-
vation) treated with primary percutaneous intervention at Lahey Clinic from June 2001 to
May 2003. Of the 132 patients studied, 85 had all 5 necessary variables to determine the
presence of metabolic syndrome. Metabolic syndrome was defined by meeting 3 (or
greater) of 5 criteria as outlined by NCEP. Body Mass Index (BMI) greater than 28.8kg/
m2 was substituted for waist circumference.
Results: 50 of 85 (58.8%) patients met the NCEP diagnostic criteria for metabolic syn-
drome. Of these 50 patients, 4 had prior history of diabetes. Twelve (26%) new diag-
noses of diabetes were made in those with metabolic syndrome. Of the other 35 patients,
two had a prior history of diabetes and two new diagnoses of diabetes were made. The
mean Framingham Risk Score for those patients with MS was 6 and for those without MS
was 5.
Conclusion: Metabolic syndrome is an underrecognized global risk factor for the develop-
ment of myocardial infarction. Metabolic syndrome is highly prevalent in young patients
with MI. Conventional risk assessment tools may not adequately identify “global” coro-
nary risk in such patients.
250A ABSTRACTS - Myocardial Ischemia and Infarction JACC March 3, 2004
M
yo
ca
rd
ia
l I
sc
he
m
ia
 a
nd
 In
fa
rc
tio
n
1021-101 Association of Glomerular Filtration Rate on 
Presentation With Subsequent Mortality in Non- ST 
Elevation Acute Coronary Syndromes
Raphaelle Dumaine, C Michael Gibson, Duane S. Pinto, Sabina A. Murphy, David A. 
Morrow, Hans-Peter Hobbach, Stephen D. Wiviott, Christopher P. Cannon, Elliott M. 
Antman, Eugene Braunwald, TIMI Study Group, Boston, MA
Background: Renal function impairment is associated with poor prognosis in the setting
of ST-elevation myocardial infarction.
Methods: We hypothesized that decreased glomerular filtration rate (GFR) was associ-
ated with poor short- and long-term prognosis in patients with non ST-elevation acute
coronary syndromes (NSTE-ACS). Data were pooled from NSTE-ACS TIMI trials, and
patients were divided in 3 groups: with normal (>=90 mL/min/1.73m2,group 1, n=4952),
mildly decreased (60-89 mL/min/1.73m2, group 2, n=6262) and moderately to severely
decreased GFR (<60 mL/min/1.73m2, group 3, n=2093) on presentation.
Results: Mortality increased stepwise with decreasing GFR: 1.27%, 2.11%, and 5.02%
at 30 days and 2.47%, 3.79% and 9.53% at 6 months in groups 1, 2, and 3 respectively
(p<0.0001 for both). The combination of TIMI risk score (TRS) tertiles and decreasing
tertiles of GFR provided further mortality stratification with highest 6-month mortality rate
(15.44%) in lowest GFR combined with highest TRS (figure). Furthermore, decreased
GFR was associated with mortality independent of TRS (at 30 days, OR=1.41 in group 2,
p=0.03; OR=3.11 in group 3, p<0.001). In addition, stroke incidence at 30-day increased
with decreased GFR: 0.33%, 0.59% and 1.27 % in groups 1, 2, and 3 respectively
(p<0.0001).
Conclusion: In the setting of NSTE-ACS, impaired GFR is associated with increased 30-
day and 6-month mortality independent of TRS, and is associated with increased stroke
incidence at 30 days.
1021-102 Underachievement of Low-Density Lipoprotein 
Cholesterol Goal in Patients on Statins in Clinical 
Practice: Are We Using Low Doses of Statins Too 
Often?
Alexandria J.M. Braganza, Gemma Eminowicz, Sabina A. Murphy, Peter M. DiBattiste, 
Gregory C. Flaker, Christopher P. Cannon, Brigham and Women's Hospital, Boston, MA
Background:Although clinical trials have found significant reductions in cardiovascular
events when using fixed doses of statins (e.g. 40 mg of simvastatin or pravastatin), in
clinical practice, treatment is usually initiated at lower doses. It is not clear, however, if in
clinical practice, the doses are titrated upward after the initial dose.
Methods: Among 2220 patients with non-ST elevation acute coronary syndromes, we
examined the statin doses used in those receiving statins at the time of entry in the TAC-
TICS-TIMI 18 trial, and their relationship to the measured low-density lipoprotein choles-
terol (LDL-C) on admission.
Results: At study entry, 722 (33%) patients were on statins, of whom 372 had LDL-C
measurements available: 132 (35%) were on atorvastatin, 126 (34%) on simvastatin, 58
(16%) on pravastatin, and 15% on other statins. The doses used are shown in the Figure.
Only 17% and 36% of patients were treated with the 40 mg doses of pravastatin or simv-
astatin as used in clinical trials. Only 1% of patients were treated with 80mg atorvastatin.
At entry, only 47% of these patients had LDL-C <100 mg/dl. At 6 months, although more
patients (1129, 51%) were on statins, the doses of statins used were not higher than
those used at baseline.
Conclusion: With the large number of patients on low doses of statins, and the majority
not being at LDL-C goal, our data suggest that, in addition to previously documented
underutilization of statins in clinical practice, there is also under-dosing of this important
class of drugs.
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1022-79 Is Early Prehospital Administration of Abciximab 
Superior to Periprocedural Therapy in Patients With ST-
Segment Elevation Myocardial Infarction and Planned 
Percutaneous Coronary Intervention? Early and Late 
Results From the Randomized REOMOBILE Pilot Study
Hans-Richard Arntz, Joachim Schröder, Klaus Pels, Bernhard Witzenbichler, Peter 
Schwimmbeck, Dirk Müller, Heinz-Peter Schultheiss, Benjamin Franklin Medical Center, 
Berlin, Germany
Background: Pre-treatment of pts with STEMI with abciximab already in the mobile inten-
sive care unit (MICU) is believed to facilitate percutaneous coronary intervention (PCI)
and improve outcome.
Methods: We randomised 100 pts with STEMI (age <80 yrs, symptoms <6hrs) to receive
weight adjusted abciximab at the scene (PTx, n=52) or at intervention in the cath lab
(HTx, n=48). All pts received 500 mg aspirin and 70 U/kg heparin in the MICU.
Results: Groups were balanced for sex (19% female), age (median 63 yrs), localisation of
MI (39% anterior) and symptom duration to arrival of MICU (median 50 min). Median
duration of symptoms until abciximab injection was 68 min in pts with PTx and 164 min
with HTx. Symptom duration to 1st visualisation of infarct related artery was 142 min in
pts with PTx and 152 min with HTx respectively. ST segment resolution after 60-90 min
(before PCI with PTx) was < 30% in 39%, 30-70% in 37% and >70% in 24% of pts, com-
pared to 56%, 14%, and 30% with HTx respectively. With PTx initial TIMI-flow 0/1 was
present in 48%, and TIMI-flow 2/3 in 52%, compared to 52% and 48% with HTx respec-
tively. Blush grade before intervention with PTx was 0/1 in 63%, and 2/3 in 37%, com-
pared to 66% and 34% with HTx respectively. Stents were successfully placed in 93% of
pts. TIMI-flow 3 was achieved in 88% of pts with PTx and 82% with HTx. None of the dif-
ferences were significant. Results tended to be in favour of PTx in pts who were treated
within the 1st hour after symptom onset independent of the time interval between start of
treatment and 1st visualisation of IRA. One HTx-pt died on day 4 after prolonged resusci-
tation, two pts had major bleeds (1 PTx, 1HTx). Urgent CABG was performed in 7 pts (4
PTx, 3 HTx) until day 5. Until day 180, three pts with PTx had reinfarctions, two within 30
days, one during month 4. Ten pts had ischemia driven re-PCI of IRA (5 PTx, 5 HTx),
three of these within the first 30 days after the index event.
Conclusion: Pre-hospital application of abciximab is safe and feasible. However, in some
contrast to previous reports we found only minor advantages of abciximab pre-treatment
in pts with STEMI and planned PCI. Also fast-track pre-hospital procedures in general
may have added essentially to the excellent outcome of the pts.
Fasting glucose 
(mg/dl)
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m2)
Total Chol. 
(mg/dl)
Mean Value
MS+
126 38 216 32 200
Median Values 
MS +
117 37 182 32 194
Mean Value
MS -
110 44 119 26 182
Median Value
MS-
102 42 117 26 174
